Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria - Report of a Meeting Held 16-18 December 2003 Geneva
(2003; 199 pages) View the PDF document
Table of Contents
Open this folder and view contentsSummary: Observations and some ways forward
Open this folder and view contentsWelcome
Open this folder and view contentsFixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective
Open this folder and view contentsProduct costs of fixed-dose combination tablets in comparison with separate dispensing and or co-blistering of antituberculosis drugs
Open this folder and view contentsFixed-dose combinations: artemisinin-based combination therapies for malaria treatment
Open this folder and view contentsDeveloping combinations of drugs for malaria examination of critical issues and lessons learnt
Open this folder and view contentsSafety and long-term effectiveness of generic fixed-dose formulations of nevirapine-based HAART amongst antiretroviral-naïve HIV-infected patients in India
Open this folder and view contentsEffect of introduction of fixed-dose combinations on the drug supply chain: experiences from the field
Open this folder and view contentsEffect of fixed-dose combination (FDC) medications on adherence and treatment outcomes
Open this folder and view contentsEffect of fixed-dose combination (FDC) drugs on development of clinical antimicrobial resistance: a review paper
Close this folderFixed-dose combination (FDC) drugs availability and use as a global public health necessity: intellectual property and other legal issues
View the documentExecutive summary
View the documentIntroduction
View the documentIPRs and Fixed-dose Combinations: Introduction to the “Anticommons Problem”
View the documentIPRs and Fixed-dose Combinations: The “Anticommons Problem” (II)
View the documentOvercoming IP/Legal barriers
View the documentBack to the Future: TRIPS, Public Health, Access to Medicines
View the documentRecommendations
View the documentConclusions
View the documentReferences
Open this folder and view contentsPharmaceutical development and quality assurance of FDCs
View the documentAnnotated agenda
View the documentList of participants
 

IPRs and Fixed-dose Combinations: Introduction to the “Anticommons Problem”

Garrett Hardin’s “tragedy of the commons” 2 conceptualized resource overutilization topics such as overgrazing on renewable crops, species extinction, and market behavior. In each case, an under assignment or inability to enforce property rights leads to a set of incentives that cause overuse of a commonly-held property resource. In Hardin’s view, too many owners of a common resource, each having the right to use, leads to overuse. Heller and Eisenberg3 have developed the mirror image “tragedy of the anticommons” in which an over assignment of property rights for a privately-held resource leads to under utilization of the resource. In the “anticommons”, multiple owners each have the right to exclude others from a resource and this leads to underuse since no one person can use the whole. One example occurs when patents for gene fragments in biomedical research lead to lack of freedom to operate since users of whole genes in downstream applications are required to license numerous already-patented gene fragments. The “cost of doing business” in this environment can be disruptive. Many IP stakeholders drive up the cost of establishing value for the IP and incompatible ownerships require individual negotiations. Within the communities of scientists, university technology transfer professionals, and private firms in the pharmaceutical and biotechnology industries, “there seems to be a widely shared perception that negotiations over the transfer of proprietary research tools present a considerable and growing obstacle to progress in biomedical research3.”

to previous section to next section
 

Last updated: May 3, 2013